ef, Autore presso Nouscom

Stefano Colloca | MD

Stefano was a co-founder of Okairos and served as the company’s Senior Director for Vector Development. Today he also leads GMP manufacturing at Keires’ subsidiary in Italy. Stefano’s experience [...]

LSP

Dr Morena D’Alise (VP of Immunology) presented as invited expert speaker at the Annual Neoantigen Summit Europe 2023, Amsterdam April 24-26 

PRESENTATION TITLE: Viral Vectored Vaccines Targeting Tumor Neoantigens elicit potent and effective anti‐tumor immune response. Please find the full report below:

5Am

Cinzia Traboni | PhD

Cinzia is Nouscom co-founder and Senior Director of Regulatory Affairs since year 2015. Her previous experience included 17 years at the Merck laboratory in Rome (IRBM), mainly as a group leader [...]

Elisa Scarselli | MD

Elisa joined Okairos in 2010 as the company’s Clinical Director. Prior to Okairos, she was a Scientist at IRBM / Merck since 1992, where she worked first on Hepatitis C infection and immunity and [...]

Mventures

Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses

D’Alise et al, Clin Cancer Res 2024

Nouscom presentation of a Late-Breaking Abstract on Translational Phase 1b data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, at AACR 2023

PRESENTATION TITLE: Nouscom presentation of a Late-Breaking Abstract on Translational Phase 1b data of NOUS-PEV, a Personalized Neoantigen Cancer Immunotherapy, at AACR 2023

Marina Udier | PhD

Marina joined Nouscom in 2016 as the Chief Operating Officer from Versant Ventures where she was an Operating Principal. Prior to Versant, Marina was at Novartis Pharma in Basel in various senior [...]